<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ATRASENTAN - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for ATRASENTAN">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">‚Üê Back to Index</a>

        <header class="medication-header">
            <h1>ATRASENTAN</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>ATRASENTAN</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Atrasentan specifically targets the endothelin system, which is a naturally occurring vasoregulatory pathway first discovered in 1988. Atrasentan functions as a selective endothelin-A receptor antagonist with approximately 1,800-fold selectivity for ETA over ETB receptors. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. Atrasentan is a synthetic pharmaceutical compound with synthesized through pharmaceutical processes rather than extracted from natural sources. There is no documented historical isolation or extraction from natural sources, nor evidence of traditional medicine use. The compound is not produced via fermentation or biosynthetic methods, and rather through synthetic organic chemistry processes.</p>

<h3>Structural Analysis</h3> Atrasentan is a pyrimidine-based compound that works to exhibit direct structural similarity to naturally occurring compounds. Additionally, its target - the endothelin system - is a naturally occurring regulatory pathway in human physiology. The compound functions as an antagonist at endothelin-A (ETA) receptors, which are endogenous G-protein coupled receptors involved in vascular regulation, renal function, and cellular proliferation.

<h3>Biological Mechanism Evaluation</h3> Atrasentan specifically targets the endothelin system, which is a naturally occurring vasoregulatory pathway first discovered in 1988. Endothelin-1 is an endogenous peptide that plays crucial roles in vascular homeostasis, renal function, and cellular regulation. By selectively blocking ETA receptors while preserving ETB receptor function, atrasentan modulates this natural system to restore physiological balance in disease states where endothelin signaling is dysregulated.

<h3>Natural System Integration</h3> (Expanded Assessment) Atrasentan targets naturally occurring ETA receptors that are part of evolutionarily conserved cardiovascular and renal regulatory systems. The medication works to restore homeostatic balance in conditions where endothelin-1 signaling becomes pathologically elevated, such as in diabetic nephropathy and pulmonary arterial hypertension. By selectively modulating this endogenous system, it enables natural repair mechanisms to function more effectively, particularly in renal and vascular tissues. The compound facilitates return to natural physiological state by reducing pathological vasoconstriction and fibrosis while preserving beneficial ETB-mediated vasodilation and natriuresis.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Atrasentan functions as a selective endothelin-A receptor antagonist with approximately 1,800-fold selectivity for ETA over ETB receptors. It modulates the binding of endothelin-1 to ETA receptors, thereby inhibiting downstream signaling pathways involved in vasoconstriction, inflammation, and fibrosis. This selective blockade preserves the beneficial effects of ETB receptor activation, including vasodilation, natriuresis, and endothelin-1 clearance.</p>

<h3>Clinical Utility</h3> Atrasentan has been primarily investigated for treatment of diabetic nephropathy, where it has shown ability to reduce albuminuria and slow progression of chronic kidney disease. The medication has also been studied in pulmonary arterial hypertension and certain cancers where endothelin signaling is dysregulated. Its safety profile includes predictable fluid retention due to its mechanism of action, requiring monitoring and potential combination with diuretics.

<h3>Integration Potential</h3> The medication&#x27;s selective targeting of an endogenous regulatory system makes it compatible with naturopathic approaches focused on supporting natural physiological processes. It could create a therapeutic window for natural interventions by reducing pathological endothelin signaling while preserving homeostatic functions. Practitioners would require education on endothelin physiology and appropriate patient monitoring protocols.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Atrasentan is not currently FDA-approved and has undergone extensive Phase III clinical trials. The compound has been granted Fast Track designation by the FDA for treatment of diabetic nephropathy. International regulatory agencies have shown interest based on clinical trial results, though formal approvals are pending.</p>

<h3>Comparable Medications</h3> Other endothelin receptor antagonists like bosentan and ambrisentan are approved for pulmonary arterial hypertension, establishing precedent for this drug class. These compounds target the same endogenous endothelin system, though with different receptor selectivity profiles.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>ATRASENTAN</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">‚úì</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">‚úì</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">‚òê</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Atrasentan is a laboratory-produced compound with no direct natural derivation. Additionally, it demonstrates significant integration with natural systems through its selective targeting of endogenous endothelin-A receptors.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>While structurally synthetic, atrasentan functionally interfaces with the naturally occurring endothelin system, specifically targeting ETA receptors that are part of normal cardiovascular and renal physiology.</p><p><strong>Biological Integration:</strong></p>

<p>The medication integrates with natural systems by selectively modulating endothelin-A receptors while preserving endothelin-B receptor function, thereby working within the body&#x27;s existing vasoregulatory framework to restore physiological balance.</p><p><strong>Natural System Interface:</strong></p>

<p>Atrasentan works within the evolutionarily conserved endothelin system to restore homeostatic balance in conditions where this natural regulatory pathway becomes dysregulated, enabling endogenous repair mechanisms to function more effectively.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>The medication demonstrates a predictable safety profile related to its mechanism of action, with fluid retention being the primary concern. It offers a targeted approach to modulating endogenous systems compared to more broadly acting interventions.</p><p><strong>Summary of Findings:</strong></p>

<p>ATRASENTAN provides essential therapeutic benefits through mechanisms that integrate with natural physiological processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank Online. &quot;Atrasentan&quot; DrugBank Accession Number DB06145. University of Alberta. Available at: https://go.drugbank.com/drugs/DB06145 2. Heerspink HJL, Parving HH, Andress DL, et al. &quot;Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.&quot; Lancet. 2019;393(10184):1937-1947.</li>

<li>Yanagisawa M, Kurihara H, Kimura S, et al. &quot;A novel potent vasoconstrictor peptide produced by vascular endothelial cells.&quot; Nature. 1988;332(6163):411-415.</li>

<li>PubChem. &quot;Atrasentan&quot; PubChem CID 148192. National Center for Biotechnology Information, National Library of Medicine.</li>

<li>Dhaun N, Webb DJ. &quot;Endothelins in cardiovascular biology and therapeutics.&quot; Nature Reviews Cardiology. 2019;16(8):491-502.</li>

<li>U.S. Food and Drug Administration. &quot;Fast Track Designation for Atrasentan in Diabetic Nephropathy.&quot; FDA Fast Track Programs Database.</li>

<li>7. Kohan DE, Rossi NF, Inscho EW, Pollock DM. &quot;Regulation of blood pressure and salt homeostasis by endothelin.&quot; Physiological Reviews. 2011;91(1):1-77.</li>

<li>Webb DJ, Neutel JM, Kramer BK, et al. &quot;Endothelin receptor antagonism: clinical evidence and future directions.&quot; Current Hypertension Reports. 2020;22(7):52.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>